fda reconsiders tirzepatide fda changes to tirzepatide Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage-bsmoothhr US FDA to reconsider decision

It is well known that malonyl-CoA is the key regulator of LCFA oxidation in the heart because it is the physiological and potent inhibitor of CPT I which transports LCFA from cytoplasm into mitochondria [42,43,44,45]

The rationale behind this approach lies in the potential of L-carnitine to enhance fat oxidation during the postprandial (after-meal) period

Merck and others are developing GLP-1s (MK-8521, orforglipron licensing, etc.), but as of 2026 none have announced capacity builds because their products are not yet commercial

M., & Goldberg, M

Meanwhile, molecular glues may directly bridge USP8 with E3 ubiquitin ligases through their unique mechanisms to form complexes, mediating more streamlined degradation